Oppenheimer Starts BioLife Solutions (BLFS) at Outperform

Oppenheimer analyst Suraj Kalia initiates coverage on BioLife Solutions (NASDAQ: BLFS) with a Outperform rating and a price target of $22.00.

The analyst comments "BioLife is a unique derivative play on the whole regenerative medicine space, with its proprietary cryopreservation media for cell therapies and biologistics for cell transport all through the continuum of development to commercialization. A diversified revenue stream from a client base of 2,000-3,000 (Novartis, Pfizer, Gilead, Intrexon, Mayo Clinic, BlueBird, etc.) evaluating 400+ applications should allow BioLife to grow at a CAGR of ~30-35% over the next few years, positioning it in the first innings of a long-term secular growth cycle. We recommend this stock, especially for growth-oriented investors looking for lower-risk exposure to the regenerative medicine space."

For an analyst ratings summary and ratings history on BioLife Solutions click here. For more ratings news on BioLife Solutions click here.

Shares of BioLife Solutions closed at $15.14 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery